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INTRODUCTION: 
Asthma is the most common chronic disease in children, affecting more than 6.1 million 
children under the age of 18 in the US (Center for Disease Control, 2015). Asthma is 
characterized by persistent airway inflammation, hyper-responsiveness to bronchodilators, 
reversible and variable airflow obstruction which leads to respiratory symptoms that vary in 
terms of frequency and severity over time (Bonini and Usmani, 2018). Asthma is a significant 
burden to the healthcare industry, resulting in 439,000 hospitalizations and 1.8 million 
emergency department (ED) visits, contributing to 3,518 deaths in 2016, 209 of whom where 
children (CDC, 2016). None-adherence to asthma medication is a common problem in patients 
with asthma, especially in children, leading to more frequent asthma exacerbations, ED visits and 
hospital admissions (McGrady and Hommel, 2013). Current methods of assessing for adherence, 
including self-report and pharmacy record, often overestimate actual adherence, making them 
unreliable means of supporting clinical decision making (Desai and Oppenheimer, 2011). 
Electronic monitoring devices (EMDs) are more accurate means of assessing for adherence but 
are not currently used in practice. The objective of this study was to determine whether a mobile-
based reminder system paired with EMDs could improve pediatric asthma medication adherence.  
 
SPECIFIC AIMS:  
Pediatric with physician-diagnosed persistent asthma in the Hartford community were 
recruited into this study to assess the feasibility and utility of EMD technology in this at-risk 
population. It was hypothesized that by combining a mobile-based reminder system paired with 
EMDs and patient education through adherence feedback, there would be an increase in 
adherence to asthma medications in children with persistent asthma.  
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BACKGROUND -  
Optimal asthma management is dependent on adequate control of asthma symptoms, and 
prevention of exacerbations. Exacerbations require bronchodilator usage and severe 
exacerbations results in treatment with systemic corticosteroids and may require hospitalization 
or stays in the intensive care unit (Lasmar et al, 2009). For patients with persistent disease, where 
symptoms are not relieved with inhaled beta-2 agonists (“reliever” medication) alone, the 
mainstay of therapy relies on inhaled corticosteroids (ICS), also known as “preventer” or 
“controller medication”. ICSs typically require daily administration to achieve adequate efficacy, 
along with proper technique and regular dosage timing (Gillette et al, 2016). Adequate adherence 
to ICSs has been shown to be integral in controlling asthma symptoms as well as in preventing 
ED visits and hospitalizations (Barnes et al, 2015). Studies have shown that adherence rates of at 
least 75% - 80% are required for adequate asthma control (Lasmar et al, 2009; Williams et al, 
2011). Yet, extensive studies report suboptimal adherence rates, especially in children, where 
reported rates of adherence are typically <50% (Engelkes et al, 2015; Morton et al, 2014). 
Several factors have been shown to contribute to medication non-adherence, including low 
socioeconomic status, low literacy, medication cost, access to care, language barriers, as well as 
parent-child relationships (Bidwal et al, 2016; Burgess et al, 2011).  
 Poor adherence to anti-inflammatory therapy in the form of ICS is associated with 
significant asthma morbidity and mortality (Milgrom et al, 2002; Milgrom et al, 1996; Cote et al, 
2003).  Non-adherence to asthma medication leads to overuse of reliever medication and more 
frequent severe asthma exacerbations, leading to more frequent ED visits and hospital 
admissions, resulting in increased healthcare utilization and cost (Puranik et al, 2016, McGrady 
and Hommel, 2013). Additionally, children with poor adherence are more likely to have 
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worsened lung function (Morton et al, 2014). A recent report from the United Kingdom 
demonstrated that 34% of deaths due to asthma are associated with poor adherence, further 
emphasizing the significance of this problem (Royal College of Physicians, 2014). While various 
interventional studies have been conducted on asthma medication adherence in children, many 
studies are limited by the subjective nature of measurements for adherence (Desai and 
Oppenheimer, 2011). A recent review found that a major limiting factor to clinical trials on 
severe asthma is an inadequate assessment of adherence to maintenance therapy, resulting in 
increased costs of trials as well as loss of statistical power (Mokoka et al, 2019). Self-reported 
adherence to asthma medication, which is the most common way to assess adherence in research 
studies, often overestimates medication adherence, making accurate assessment and intervention 
difficult for clinicians (Bender et al, 2004, Burgess et al, 2008). In one study on inner-city 
children, parents’ report on their child’s adherence to asthma medications was 85%, compared 
with <25% when measured using pharmacy refill records (Otsuki et al, 2009). Outside of verbal 
reports of adherence, questionnaires and diaries have also been employed to quantify and 
potentially standardize adherence rates. However, these methods have also been shown to 
overestimate actual adherence (Lam and Fresco, 2015). Other, more quantitative methods, such 
as weighing canisters, dose counters on inhalers, and calculating medication possession ratio 
using prescription refill data have all been studied as more objective ways of monitoring 
adherence. However, the reported adherence from each method varies greatly, and none can 
accurately measure true consumption of medications (Bender et al, 2000, Krishnan et al, 2012, 
Sumino et al, 2013, Chung et al, 2000). Furthermore, physician judgment of patient adherence, a 
key component to understanding disease management and optimizing treatment planning, is also 
inaccurate (Pearce and Fleming, 2018).  
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The usage of electronic monitoring devices (EMDs) offers a much more accurate and 
objective view of adherence and has since been proposed as the possible “gold standard” for 
measuring adherence due to its ability to offer time-sensitive information (Riekert and Rand, 
2002). Studies that compare usage of EMDs against other forms of adherence measurements 
consistently find that EMDs are more accurate and provide adherence rates that are much lower 
than traditional means of measuring adherence (Bender et al, 2000; Riekert and Rand, 2002; 
Pilcher et al, 2015). Though there is variability in the design and implementation of these EMDs, 
most share common features, including a sensor to track actuations of inhalers, ability to track 
doses using some form of sync function, and the ability to access adherence data for patients 
and/or clinicians (Chan et al, 2015). One of the earliest EMDs introduced in clinical trial was 
Doser, which was made commercially available in 1997. Despite clinical trials validating the 
accuracy of this technology against other means such as canister weighing, as well as relative 
low cost, the Doser is not commonly used in clinical practice today (Simmons et al, 1998; 
O’Connor et al, 2004). Thus, despite clear advantages in measuring adherence rates, these 
devices are not routinely used as part of interventions geared to improve medication adherence, 
likely due to the cost associated with implementing such technology in the general public. 
Additionally, lack of consistent research showing improved health outcomes have limited uptake 
of insurance coverage for EMDs.  
Recently, a growing body of literature on mobile technologies and remote patient 
monitoring have been proposed as cost-effective ways of improving medication adherence in 
chronic diseases, especially in children and adolescents (Van Gaalen et al, 2012; Mulvaney et al, 
2013; Fedele et al, 2017). In this age group, self-management of asthma, which includes not only 
adherence to medications, but also behaviors to monitor and prevent symptoms such as avoiding 
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asthma triggers, are often limited in scope (Bruzzese et al, 2012). Thus, technologic interventions 
offer a potentially viable modality of behavioral change, especially in the management of 
asthma. A number of studies have shown improvements in medication adherence through 
incorporation of electronic reminders using text message reminders (Petrie et al, 2012; Britto et 
al, 2017; Vasbinder et al, 2016). A pilot study done at the University of Cincinnati (n = 62) 
looked at the effects of text message reminders over 3 months and found that there was an initial 
2.75% increase in adherence compared to baseline as measured by EMDs. However, such a 
difference was not sustainable by the end of the study (Britto et al, 2017).  In a multicenter RCT, 
another study looked at the utilization of short text message reminders on adherence to ICS in 
children ages 4 - 11 over a span of 12 months. Text message reminders were sent to parents and 
children, if they possessed a mobile phone, when missed doses were recorded using EMDs. The 
study found that mean adherence over the total period of the study was higher in the intervention 
vs control (69.3% vs 57.3%) as measured by EMDs. While there was a significantly higher rate 
of adherence within the first six months, such high rates did not persist during the remainder of 
the study period. Additionally, it found no differences in asthma control, quality of life, or 
asthma exacerbations (Vasbinder et al, 2016). Another study conducted in New Zealand (n = 
216) also looked at the effects of a text message reminder system on adherence to asthma 
medications in adults aged 16 – 45. The study found that the intervention group had a higher 
average rate of self-reported adherence when compared to control (57.8% vs 43.2%). A key 
limiting factor to this study was the reliance on self-reported adherence. While these studies 
show some promise in increasing adherence rates immediately after initiation of the intervention, 
they demonstrated that simple reminder systems may be inadequate in addressing long-term 
behavioral changes (Apter et al, 2012).  
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While the concept of utilizing EMDs in management of asthma is not a new concept, the 
integration of this technology into clinical practice has not been extensively studied. In studies 
looking at the accuracy of utilizing inhaler trackers, they have shown consistently high accuracy 
and reliability (Bonini and Usmani, 2018). In the pediatric population, studies have assessed 
changes in asthma adherence after utilization of EMDs, often in concert with electronic 
reminders and/or clinician feedback. However, most studies are small in study size and short in 
clinical follow up. One study (total n = 26) assessed the usage if an EMD along with adherence 
feedback and found that adherence was significantly higher in the intervention group (79% vs 
58%) after four months. A study with a larger study size (n = 90) assessed the role of EMDs, 
daily reminder alarms along with adherence feedback found  significantly improved adherence in 
the intervention group compared to the control (70% vs 49%) but did not find significant 
differences in asthma control or lung function. Additionally, the EMD utilized was not able to 
relay real-time adherence information for the participant or the participants’ parents until follow-
up visits, when adherence information was reviewed for feedback with the clinician (Morton et 
al, 2016). These studies show that while EMDs may increase adherence, more research is needed 
to elucidate how EMDs can best be implemented in the clinical setting .  
Inherently, the nature of adherence is multifaceted and effective treatment cannot merely 
rely on reminder systems. Barriers to adherence may be “intentional”, such as having doubts or 
concerns about treatment effectiveness or side effects, or “unintentional”, such as forgetfulness 
and lifestyle barriers (ref). Reminder systems target the unintentional barriers to adherence, but 
lack the educational intervention needed to target intentional barriers (Foster et al, 2014). While 
mobile technology offers a unique way to address adherence in real-time, few studies have 
looked at the effects of a combination of audiovisual reminders and feedback from medical 
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providers on patient adherence in order to address intentional barriers to adherence. Feedback 
alone has been shown to increase adherence, but such studies are limited by the size of study 
sample (Onyirimba et al, 2003; Spaulding et al, 2012). In a systematic review of interventions 
intended to improve adherence to inhaler medications in chronic lung disease, results indicate 
that the combination of electronic monitoring with feedback was associated with significant 
improvement in adherence (Pritchard and Nicholls, 2013). By combining mobile-based reminder 
alarms with clinician feedback using real-time adherence from EMDs, both unintentional and 
intentional barriers to adherence can be addressed. Real-time monitoring of adherence provides 
greater insight regarding medication behaviors for physicians to better understand their patients, 
creating both the educational opportunity to address both types of barriers to adherence through 
clinical feedback. Additionally, this creates an opportunity to better direct care coordination 
efforts in order to address socioeconomic barriers to adherence as well.  
Non-adherence to asthma therapy is greatly influenced by socioeconomic factors 
(Mazumdar et al, 2015). This is especially true in Connecticut, where childhood asthma 
prevalence is consistently higher than that of the national average (11.3% compared to the 
national average of 8.2% ref). In Connecticut, the highest prevalence of asthma is in the Hartford 
community, consistent with national data that shows asthma prevalence is disproportionally high 
among children from low-income and minority families as well as children that reside in inner-
city neighborhoods (Collaborative for Asthma Equity in Children, 2016; Nepaul et al, 2012; 
Scope et al, 2016). Healthcare utilization due to asthma in children is also significant in this 
population, resulting in 241.7 ED visits and 41.5 hospitalizations per 10,000 people, which is 
significantly higher than the national average of 51.7 ED visits and 18.3 hospitalizations per 
10,000 people (Collaborative for Asthma Equity in Children, 2016; CDC, 2015). In children with 
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severe, poorly controlled asthma, poor adherence to ICSs is viewed as an important contributor 
to poor asthma control resulting in further exacerbations requiring ED visits and hospitalizations. 
Studies consistently show that lower socioeconomic status is associated with poorer asthma 
control in children with asthma, with non-adherence adversely affecting those with low income 
and education levels (Gong et al, 2014; Scope et al, 2016). Adolescents are particularly at risk 
for non-adherence as asthma mortality in this group is approximately twice that of younger 
children (Akinbami and Schoendorf, 2002). Self-management of asthma in adolescents is 
limited, and barriers to achieving adequate control are multifaceted, with contributing factors 
including lack of patient knowledge of disease, poor understanding of the benefits of medication, 
forgetfulness, and negative attitude towards asthma (Holley et al, 2017). Currently, most 
interventions designed to improve adherence in this age group are geared towards educational 
and behavior modification interventions, including educational materials, individual and group 
sessions, and follow-up phone calls (Bender et al, 2003). With the advent of EMDs, increasing 
efforts are geared towards empowering adolescents to gain greater independence through 
improved self-management of chronic diseases by implementing such technologies.  
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METHODS: 
Study Design -  
  This study was a prospective, randomized, controlled trial of children with persistent 
asthma who are managed on daily ICSs. The goal of the study was to enroll 75 children, 
randomized 2:1 into the intervention arm and the control arm, respectively. Such a sample size 
was chosen due to the supply of EMDs (50) we had available to use for the study. The study 
population consisted of children ages 8-17 years old with physician-diagnosed persistent asthma. 
Participants needed to have been prescribed an ICS for at least one month using a pressurized 
metered dose inhaler (pMDI) or dry powder inhaler that is compatible with the HeroTracker 
EMD (Table 1; Figure 2A). The child or the parent/guardian, whoever was the main person who 
administered the child’s medications, must have had a compatible smartphone with Bluetooth 
capabilities. Patients had to be English or Spanish speaking. Patients with other co-morbidities 
(including other types of chronic lung disease, chronic medical conditions such as congenital 
heart disease) were excluded from the study. Patients who were or planned on becoming 
pregnant were also excluded from the study.  
Participants were recruited from the Connecticut Children’s Medical Center’s (CCMC) 
Pulmonary clinic in Hartford, Connecticut. Participants were approached to participate during 
regular visits to the pulmonary clinic. After verification of study eligibility based on inclusion 
and exclusion criteria, the details of the study were discussed in detail with the child and parent 
present at the visit. If the parent agrees for the child to participate, written consent from the 
parent as well as assent from the participant were obtained by study personnel. Participants were 
then stratified by age at the time of enrollment (8-13 years, 14-17 years), and randomly assigned 
into the intervention or control group using computer-generated block randomization with block 
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sizes of three, six, or nine. Due to the nature of the study, the participants, research personnel and 
the clinicians were not blinded.  
After enrollment, each participant was followed at 3 months (+/- 20 days) and at 6 
months (+/- 20 days) (Figure 1). The follow up appointments were meant to correlate with 
regularly scheduled follow up appointments for participants.  
 
 
 
Figure 1. Study Design. 
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Table 1. Pressurized metered dose inhalers (pMDI) compatible with the 
HeroTracker EMD. 
  
 
Daily Control  
Advair Diskus (100/50 mg), (250/50 mcg), 
(500/50 mcg) 
Dulera 100/5 mcg and 200/5 mcg 
Advair HFA (45/21 mcg), (115/21 mcg), 
(230/21 mcg) 
Duolin HFA 20 mcg 
AeroSpan 80 mcg (60 count) and (120 count) Flovent 44 mcg, 110 mcg and 220 mcg 
Alvesco 80 mcg and 160 mcg Flovent Diskus 50 mcg, 100 mcg and 250 
mcg 
Asmanex HFA Foratec HFA 12 mcg 
Asthavent 100 mcg Foster 100/6 mcg 
Atimos 12 mcg (50 count), (100 count) and 
(120 count) 
Ipvent HFA 40 mcg 
Beclate HFA 50 mcg, 100 mcg, 200 mcg  QVAR 40 mcg, 80 mcg 
Budeflam 100 mcg Serevent Diskus 
Ciclovent 160 mcg Seroflo 50 mcg,125 mcg, 250 mcg  
Clenil 50 mcg, 100 mcg, 200 mcg, 250 mcg Symbicort 80/4.5 mcg, 160/4.5 mcg, 400/12 
mcg 
Rescue  
Atrovent HFA 
ProAir HFA 
Proventil HFA 
Ventolin HFA 60 count, 200 count 
Xopenex HFA 80 count, 200 count 
  12 
 
Intervention Group: 
 The intervention arm consisted of a mobile-based platform produced by Cohero Health® 
that consists of: 1) BreatheSmart mobile application, which tracks medication usage and sends 
real time reminders based on individual treatment plans, 2) HeroTracker sensor, which is an 
EMD that counts actuation of the inhaler it is attached to, and is synced to the BreatheSmart app 
via Bluetooth technology, and 3) CoheroConnect, a HIPPA-compliant, web-based portal that 
allows researchers and clinicians, to monitor adherence in real-time (Figure 2). Using these three 
products, participants received alerts through their BreatheSmart app to take their daily 
preventive ICSs, which were typically given once daily or twice daily. Participants were given 
two HeroTracker sensors, one for the controller (ICS) and another for the rescue (albuterol) 
MDIs, allowing the app to track actuation for both types of inhalers. Study personnel along with 
clinicians were trained on how to monitor adherence using CoheroConnect. If randomized into 
the intervention arm of the study, the participant and/or the parent (whomever was the main 
person managing the participant’s daily ICS) were provided with training on how to utilize the 
BreatheSmart app at the initial intake visit. Participants were told to download the app while in 
the office and were instructed on how to sync their HeroTrackers to their phones. If participants 
were unable to do this in the office, study personnel contacted the participants after the visit to 
ensure participants did not have any issues with the installation process.  
At the 3-month follow up visit, physicians are asked to review adherence data since the 
participant’s previous visit via CoheroConnect and provided adherence feedback to the 
participant. Each feedback discussion by the physician was personalized to the participant and 
the participant’s level of adherence.   
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A)   
B)  
Figure 2. Components of BreatheSmart Intervention. A) HeroTrackers – wireless 
Blue-tooth enabled inhaled sensors that are attachable to pMDI (left) and diskus (right) inhalers. 
B) CoheroConnect– a web-based platform for clinicians to monitor participants’ adherences.  
 
Control Group: 
 Control participants were provided standard care as they would be given at a specialized 
clinic. They were not provided access to the BreatheSmart app, CoheroConnect, or an EMD. 
Participants were seen at their standard asthma clinic for regular follow up care.  
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Assessments:  
 At each visit (initial enrollment, 3-month follow up, and 6-month follow up), the 
following assessments will be performed: 
• Intake assessment:  
o Demographics: 
§ Age of the participant 
§ Ethnicity as defined by the participant and/or parent, characterized into 
“African American”, “White”, “Hispanic, non-Puerto Rican”, “Puerto Rican” 
or “Other”. During analysis, this was recoded into “African American”, “Non-
Hispanic White”, with “Hispanic, non-Puerto Rican” and “Puerto Rican” 
recoded as “Hispanic”.  
§ Gender as defined by the participant, measured dichotomously as “Female” or 
“Male” 
§ Self-reported family income, characterized as “<$15,000”, “$15,000-
$29,999”, “$30,000 – $49,999”, and “>$50,000”. During analysis, this was 
recoded into “<$30,000” or “>$30,000” 
§ Type of insurance, confirmed using electronic medical records  
o Medication list, and other potential comorbidities  
o Asthma therapy – ICS prescribed, dosage, and frequency of dosage 
o Asthma severity (physician confirmed) 
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o Asthma Control Test (ACT) score - The Asthma Control Test (ACT) is used to assess 
asthma control within the past four weeks – a score <= 19 indicates poorly controlled 
disease (Liu et al, 2006) 
o Three methods of assessing for adherence: 
§ Test of the Adherence to Inhalers (TAI) – a validated questionnaire to assess 
for adherence (Plaza et al, 2016) 
§ Self-reported adherence, which was reported by the participant and/or parent 
as the “number of doses missed per week” 
§ Pharmacy refill history over the past 6 months prior to enrollment 
o Any ED visits in the past year, measured dichotomously as “Yes” or “No” 
o Any hospitalizations in the past year, measured dichotomously as “Yes” or “No” 
o Any oral steroid use in the past year, measured dichotomously as “Yes” or “No” 
o Pulmonary Function Test (PFTs), including Forced Expiratory Volume (FEV1) and 
Fractional exhaled Nitric Oxide (FeNO), which were confirmed using electronic 
medical records.  
§ FEV1% <= 80% indicates “Not well controlled” asthma based on National 
Heart, Lung, and Blood Institute (NHLBI) guidelines (National Asthma 
Education and Prevention Program, 2007) 
§ FeNO is a measure of responsiveness to anti-inflammatory therapy, but is not 
clinically indicated for every patient. FeNO > 50 ppb (>35 ppb in children < 
12 years of age) indicates low-adherence or inadequate response to ICS based 
on American Thoracic Society (ATS) guidelines (Dweik et al, 2011) 
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• Follow-up assessment:  
• ACT score 
• TAI 
• Self-reported medication adherence 
• Pharmacy refill history since last visit 
• Number of ED visits since last visit 
• Number of hospitalizations since last visit 
• Number of oral steroid uses since last visit 
• PFTs, including FEV1 and FeNO 
• For intervention group –  
o Any technical issues related to the BreatheSmart platform 
o For those who completed six months in the study, participants were asked to 
answer a 5-item questionnaire which was scored on a 5-point semantic 
differential scale (1 = strongly disagree, 5 = strongly agree) which asked about 
topics such as acceptability of use, perceived effects on asthma control, and 
usefulness of physician feedback:  
§ “I would be happy to continue using my BreatheSmart app and 
HeroTracker” 
§ “I feel more control of my asthma now” 
§ “Knowing when to take my asthma medication is easy” 
§ “I would recommend using this to other people I know with asthma” 
§ “Going over how often I take my asthma medication with my doctor 
was helpful” 
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Study Outcomes 
 The primary outcome for this study was medication adherence as measured by pharmacy 
refill. This was used because this is the most reliable means of measuring adherence between the 
control and intervention groups. Medication adherence as measured by pharmacy refills was 
calculated using Proportion of Days Covered (PDC), a commonly used method of calculating 
adherence that is defined as a ratio of sum of unique days supplied based on refills over the total 
number of days in the period that is assessed (Choudhry et al, 2010). PDC has been shown to be 
more accurate at assessing adherence when compared to other methods (Martin et al, 2009). For 
the baseline adherence measurement, the PDC was assessed over a 6-month period prior to the 
enrollment date. The 6-month PDC was calculated over the 6-month period from the date of 
enrollment. Change in PDC was calculated as the difference between the 6-month PDC and 
baseline PDC.  
 A secondary outcome for this study was adherence as measure by EMD. Average 
adherence based on EMD is calculated using the average of daily adherence rates as recorded by 
the EMDs. Another secondary outcome is the Asthma Medication Ratio (AMR), which is a 
National Committee for Quality Assurance measurement for patients with persistent asthma. 
Using pharmacy refill data, AMR is calculated as the ratio of controller refills over the sum of 
controller refills and short-acting beta-agonist refills. Studies have shown AMR < 0.5 is 
associated with increased ED visits and hospitalizations as well as poorer quality of life (Beck et 
al, 2015; Andrews et al, 2013). Other secondary outcomes, such as ACT score, PFTs, TAI, as 
well as number of ED visits, hospitalizations, oral steroid uses, were evaluated but not presented 
in this analysis due to low number of responses.  
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Study Timeline: 
 The original study protocol was submitted for full board review through the Institutional 
Review Board (IRB) at Connecticut Children’s Medical Center on April 10, 2017. The protocol 
was approved by the IRB board on July 13, 2017. Recruitment started in January, 2018. 
Recruitment took place at the Connecticut Children’s Medical Center pulmonary clinic in 
Hartford, Connecticut.  
 
Data and Analysis: 
Because this is an ongoing study, we included in the analysis all participants who had 
been enrolled for six months as of February 1, 2019.  
Data analysis was based on an intention to treat model. Medication adherence based on 
pharmacy refill was calculated using PDC, for which the calculation has been defined elsewhere 
in literature (Choudhry et al, 2010). Medication adherence rates based on EMD was calculated 
over the span of the 6-month period, subdivided into morning and night doses, and recorded as a 
percentage. This was calculated as the ratio of doses actuated as recorded by the EMD over the 
number of doses prescribed x 100. The daily adherence was capped at 100%, to avoid falsely 
increased values due to dose dumping. The overall six monthly figure was a mean of each 
daily %. For example, if a child was prescribed two puffs twice a day, and only took two puffs 
on the first day, six puffs on the second day, four puffs on the third day, and two puffs on the 
fourth day, the daily adherence would be 50%, 100%, 100%, 50%, respectively. The average 
adherence for this time period would be 75%.  
 Between-group comparisons of adherence rates based on PDC at baseline and at six 
months were conducted using two-sample independent t-tests. To account for differences in 
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baseline adherence, changes in adherence from baseline to six months were compared between 
groups using a two-sample independent t-test. Average EMD adherence rates for the first 30 
days, 90 days, and 180 days of the study period were calculated for the intervention group. 
Additionally, AM and PM EMD adherence rates were calculated and compared using a paired t-
test. Changes in AMR (<0.5 or ≥0.5) from baseline to 6-months within groups were tested by 
McNemar test. Chi-square tests were applied to compare AMR between groups at baseline and at 
six months. All the statistical analyses were performed in SPSS. A p-value smaller than 0.5 was 
considered statistically significant. 
 
RESULTS: 
From January 2018 through February 2019, 116 individuals were approached and 
screened for eligibility to participate. Forty-three (37%) did not meet inclusion criteria and 19 
(16%) were not interested. A total of 53 participants (36 intervention, 16 control) were enrolled 
between January 2018 and February 2019. A total of 41 participants (29 intervention, 12 control) 
who had been enrolled for six months were included for this analysis. Within the control group, 
only four participants (33%) completed a 3-month follow up, and only five participants (42%) 
completed a 6–month follow up visit. Within the intervention group, only 13 participants (45%) 
completed a 3-month follow-up, and only 16 participants (55%) completed a 6-month follow-up, 
(Figure 2). This occurred due to either participants not attending or cancelling scheduled 
appointments. For those without a 3-month follow-up in the intervention group, no physician 
feedback was provided.  
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Figure 2. CONSORT diagram (updated on 2/1/2019). Participants who were enrolled in 
the study for 6 months at the time of analysis are included for this analysis. 
 
 
Demographics: 
Demographic characteristics of participants analyzed are shown in Table 2. Participants 
were on average 12.7 (SD = 3) years old, 49% were Latino, 29% were Non-Hispanic White, and 
22% were African America. The majority of participants (78%) utilized public insurance and 
slightly more than half reported a family income of less than $30,000. The majority of 
participants had moderate or severe persistent asthma (44% and 51%, respectively).  
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Total 
(n=41) 
Control 
(n=12) 
Intervention 
(n=29) 
P value 
Age (years)  12.7 (3) 12.5 (2.9) 12.7 (3.1) 0.83 
Sex (Female) 23 (55%) 6 (50%) 17 (59%) 0.43 
Race/Ethnicity  
African American 
Latino 
Non-Hispanic White 
 
9 (22%) 
20 (49%) 
12 (29%) 
 
4 (33%) 
5 (42%) 
3 (25%) 
 
5 (17%) 
15 (52%) 
9 (31%) 
 
0.53 
Public Insurance 32 (78%) 11 (92%) 21 (72%) 0.18 
Reported Family Income  
<$30,000/year 
>=$30,000/year 
 
22 (54%) 
19 (46%) 
 
8 (67%) 
4 (33%) 
 
14 (48%) 
15 (52%) 
 
0.28 
Asthma Severity 
Mild persistent 
Moderate Persistent 
Severe Persistent 
 
2 (5%) 
18 (44%) 
21 (51%) 
 
1 (8%) 
5 (42%) 
6 (50%) 
 
1 (3%) 
13 (45%) 
13 (52%) 
 
0.80 
Table 2. Demographics of study participants. Data presented as mean (SD) or N (%).  
 
 At baseline, participants had a high disease burden of asthma, as indicated by high rates 
of ED visits (56%), hospitalizations (34%), and oral steroid usage (80%) in the last year (Table 
3). Twenty-two (51%) of the participants had ACT scores <= 19, indicating poor control. 
Average FEV1% was 90.9%, with 31% of total participants having “Not well controlled” asthma 
based on NHLBI guidelines. For the participants with FeNO (n= 13), average FeNO level was 
51.4 ppb, with 50% of participants showing high levels of FeNO as defined by ATS guidelines 
(Dweik et al, 2011). At baseline, 66% of patients scored in the “poor” adherence category based 
on TAI. When asked specifically asked the question “number of missed doses per week”, 
adherence per patient report was 85.8%.  
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 Total (N=41) Control (N = 
12) 
Intervention 
(N=29) 
P 
value 
Any ED visits in the last year (N 
(%)) 
23 (56%) 7 (58%) 16 (55%) 0.57 
Any hospitalizations in the last 
year (N (%)) 
14 (34%) 3 (25%) 11 (38%) 0.34 
Any oral steroid use in the last 
year (N (%)) 
32 (80%) 8 (73%) 24 (83%) 0.38 
Baseline ACT score ≤19 (N (%)) 22 (51%) 9 (75%) 13 (45%) 0.08 
Lung function  
FEV1 <= 80% (N (%)) 
 
High FeNO (N (%)) 
 
 
12 (31%) 
 
6 (50%) 
 
 
1 (10%) 
(n = 10) 
2 (50%) 
(n=4) 
 
11 (38%) 
(n = 29) 
4 (50%) 
(n=8) 
 
0.13 
 
0.73 
Self-reported adherence (mean 
(SD)) 
85.8% (16) 90% (12) 84% (18) 0.65* 
Baseline TAI (N (%)) 
Good 
Intermediate 
Poor 
 
6 (15%) 
8 (20%) 
27 (66%) 
 
2 (17%) 
2 (17%) 
8 (66%) 
 
4 (14%) 
6 (22%) 
19 (66%) 
 
0.94 
Table 3. Baseline characteristics of participants. ACT = Asthma control test (≤19 
indicates uncontrolled asthma). FEV1% = Forced expiratory volume in 1 second, % of predicted. 
FEF 25-75% = Forced expiratory flow at 25-75%, % of predicted. FeNo = Fractional exhaled 
nitric oxide. TAI = Test of the Adherence to Inhalers. *Due to negative skewness of results, non-
parametric Mann-Whitney U test was used to test for null-hypothesis.  
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Primary Outcome 
 Adherence rates at six months based on PDC did not differ significantly between the 
control and intervention groups (Figure 3, p = 0.21). The average adherence in both intervention 
and control groups decreased from baseline to six months. At baseline, the mean adherence 
based on pharmacy refill for the control group and intervention group was 42% and 50%, 
respectively (p = 0.37). At six months after enrollment, the mean adherence for the control group 
and intervention group was 31% and 41%, respectively (p = 0.21). The adherence for the control 
group dropped on average by 11%, which was not significantly different from 9% for the 
intervention group (p = 0.83) (Table 4).  
 
 
Figure 3. Adherence based on pharmacy refill.   
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  Control (n=12) 
Intervention 
(n=29) P value 
PDC (mean (SD)) 
Baseline 
6 months 
 
42% (24) 
31% (20) 
 
50% (27) 
41% (27) 
 
0.37 
0.21 
Change in PDC (mean 
(SD)) - 11% (22) - 9% (32) 0.83 
 Figure 4. Mean adherence rates based on pharmacy refill.  
 
Secondary outcomes: 
Average adherence over the six months for the intervention group was 27.4% based on 
EMD. Higher average adherence was obtained in the initial 30 days after enrollment (56.1%), 
but this declined over time during the 6 month study period (Table 5). Of note, out of the 29 
patients in the intervention group, only 26 participants were assessed as three participants never 
used the EMD. Interestingly, when average daily adherence was plotted over time, there was an 
initial high rate of adherence of > 70% in the first week of the study, but this number dropped 
drastically after the first week (Figure 4). When comparing average adherence in the first month 
vs the overall adherence over the six months of the study, there was a statistically significant 
drop in adherence from 56.1% to 27.4% (p = 0.00). When daily adherence was further 
subdivided into AM and PM doses, there was no difference in adherence to the AM or PM doses 
(Table 5, p = 0.22 for the 180-day adherence).  
AMR did not differ significantly between intervention and control groups at baseline or 
at six months (Table 6, p = 0.73 and p = 1.00, respectively). McNemar Test also did not show 
any statistically significant changes in AMR from baseline to six months within the intervention 
group or the control group (p = 0.78 and p = 0.69, respectively).  
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Table 5. Average, AM, and PM adherence rates based on EMDs. 
 
 
 
Figure 4. Average daily adherence based on EMD.  
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Average Daily 
Adherence 
Average AM 
Adherence 
Average PM 
Adherence 
P-value* 
30 Day Adherence (mean, ±SD) 56.1% (35.1) 55.6% (34.7) 54.2% (36.6) 0.64 
90 Day Adherence (mean, ±SD) 41.2% (32.5) 39.2% (31.8) 42.4% (35.6) 0.40 
180 Day Adherence (mean, ±SD) 27.4% (27.4) 31.8 (33%) 26.2% (27.1) 0.22 
*p-value is calculated as difference between AM and PM adherence rates 
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 Intervention (N=29) Control (N=12) Chi-square test 
Baseline AMR (N, %) 
< 50% 
>= 50% 
 
12 (41%) 
17 (59%) 
 
6 (50%) 
6 (50%) 
 
0.73 
6 – month AMR (N, %) 
< 50% 
>= 50% 
 
10 (35%) 
19 (65%) 
 
4 (33%) 
8 (67%) 
 
1.0 
Table 6. Asthma Medication Ratio (AMR).  
 
Device Performance and Patient Acceptability  
 Out of the 21 participants in the intervention group who received follow-up visits, one 
participant never utilized the EMD due to changes in medication therapy. Out of the 20 
participants who utilized the EMD, 13 (65%) participants experienced technical issues. Seven 
out of the 13 participants experienced technical issues related to syncing problems between the 
EMD and the BreatheSmart app.  
 Out of the 29 participants in the intervention group, 16 participants completed the 5-item 
questionnaire on patient acceptability of the intervention at their 6-month follow up visit. Table 7 
summarizes results from this questionnaire. Patient satisfaction with the intervention was high, 
with high median scores for Questions 1 and 4 (median scores = 5 and 4, respectively). Perceived 
control of asthma symptoms (Questions 2 and 3) also had relatively high scores (median score = 
4 for both), although the mean was less than 4 for Question 2. Lastly, patient acceptability of 
physician feedback was also high (median score = 4).  
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Question N Mean (SD) Median (Q1, Q3) 
1) I would be happy to continue using my 
BreatheSmart app and HeroTracker 15 4.5 (0.7) 5.0 (4.0, 5.0) 
2) I feel more control of my asthma now 15 3.9 (1.1) 4.0 (3.0, 5.0) 
3) Knowing when to take my asthma medication 
is easy 15 4.1 (1.0) 4.0 (3.0, 5.0) 
4) I would recommend using this to other people 
I know with asthma 15 4.3 (0.8) 4.0 (4.0, 5.0) 
5) Going over how often I take my asthma 
medication with my doctor was helpful 16 4.0 (1.1) 4.0 (3.8, 5.0) 
Table 7. Patient acceptability of intervention.  
 
 
DISCUSSION: 
In this preliminary analysis of data from a part of a larger randomized, controlled trial, 
we did not see any significant differences in adherence rates between the control and intervention 
groups after six months. Additionally, there was no statistically significant change in adherence 
between the control and intervention group. Interestingly, adherence rates for both groups fell 
from baseline to 6 – months. Additionally, we did not demonstrate any significant changes in 
AMR, a measure of asthma control, within the intervention group. From our data obtained from 
EMDs, while we did see an initial high rate of adherence within the first seven days of 
intervention, this rate was not sustainable after 180 days.  
Multiple factors may have contributed to the decrease in adherence for both groups. Both 
groups lacked adequate clinical follow-up. The majority of the participants in both the control 
and intervention groups did not have a follow-up at three and six months after enrollment. Since 
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our follow-up visits are meant to align with regularly scheduled clinic visits, this meant that the 
majority of children in both groups did not receive clinically-indicated follow up visits to 
adequately monitor their asthma control. For the intervention group in particular, this meant that 
55% of participants did not receive physician feedback on adherence, a vital part of our 
intervention (Figure 2). Additionally, asthma is a highly seasonal disease. Most asthma patients 
are highly symptomatic during school months (September to June). Due to the timeline of this 
study, the majority of participants were enrolled prior to June 2018. This means baseline 
adherence was assessed over more symptomatic months, while the majority of intervention 
months occurred over less symptomatic summer months. During this time, children may be less 
adherent due to decreased symptoms and may be less likely to attend clinical follow-up visits 
due to inconsistent schedules during the summer months. This decrease in adherence over time 
for the control group is consistent with results from previous adherence interventional studies 
that have also monitored asthmatic children over study periods of six months (Morton et al, 
2017; Charles et al, 2007).  
Within the intervention group, we did not see any significant, sustainable improvements 
in adherence. While other studies have demonstrated increased adherence rates for intervention 
groups, many had continual monitoring of participants with prompt interventions (e.g. calling, 
text-messaging) when there were recordings of non-adherence registered from the EMDs. Since 
we wanted to assess whether this technology would be adaptable to this high-risk pediatric 
population, lack of close monitoring could be one of the explanations for the statistically 
significant fall in adherence after the initial seven to 30 days after enrollment. Technical 
difficulties could also have contributed to the lack of change with intervention. The high rate of 
technical difficulties (65%) amongst the intervention group indicates that this could have been a 
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barrier for implementation of technology. In particular, syncing issues seemed to have been a 
major part of the reason why these technical issues occurred. Though the tracker is supposed to 
store any doses that were actuated but not synced with the phone, it is unclear if any doses may 
have been missed due to syncing issues. Additionally, the concept of “app fatigue” is evidenced 
by the increase in usage of mobile phone apps across all age-groups (Zhao et al, 2016). Despite 
this, a study showed that 25% of people will abandon an app after one use, and 62% of users will 
use an app less than 11 times (Perez, 2016). For an intervention where efficacy is highly 
dependent on sustainable usage of the phone app, this could have been a major limiting factor for 
sustainable usage of the intervention, as evidenced by the steep drop in average daily adherence 
after the first week. Lastly, while physician feedback was meant to be individualized in nature in 
order to address both intentional as well as non-intentional barriers to adherence, it was 
impossible to monitor for consistencies in the quality of feedback that participants received at 
their follow-up appointments. We did not assess for variability in clinician approach to 
interpreting adherence data on the CoheroConnect dashboard along with the role that adherence 
feedback played in clinical decision-making, which made standardization of clinician feedback 
difficult. These factors could have all contributed to the lack of sustainable rates of adherence in 
this intervention group.  
One of the key aspects of this study was to assess for the feasibility of implementing this 
intervention in the clinical setting. As evidenced by the high variability in the adherence results 
using different modes of assessing for adherence in this study (e.g. questionnaire format using 
TAI, pharmacy refill data calculated as PDC, self-report, and adherence based on EMD), lack of 
consistent and accurate means of measuring adherence can hinder clinical decision making for 
physicians. At baseline, self-reported rates of adherence were consistently high (>80%), yet rates 
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obtained using pharmacy refill data showed adherence rates were on average less than 50%. This 
is consistent with published rates of asthma adherence in children (Sherman et al, 2000; Otsuki et 
al, 2009). While we cannot compare EMD adherence rates at baseline, the average EMD 
adherence rate at the end of the study was much lower than the average adherence rate obtained 
using PDC (27.4% vs 41%). Here, our study is consistent with other studies that have also 
demonstrated EMD adherence rates to be lower than the rates obtained using pharmacy refill and 
self-report (Bender et al, 2000; Jentzsch et al, 2009). Based on our data, due to the 
aforementioned technical issues, it is difficult to infer whether adherence rates as measured by 
EMDs are more accurate than other modes of assessing adherence. However, this does show that 
EMDs are able to relay a level of detail on patients’ health behaviors that clinicians were never 
able to see using the other methods of assessing adherence. For example, using EMDs, we were 
able to delineate between AM and PM doses. While we did not demonstrate any differences in 
missed doses based on timing of the doses, this shows that this technology can offer such 
explanation for health behaviors over time. Being able to understand patterns in health behaviors 
is the first step in being able to counsel and modify behaviors.  
This study also demonstrates that there may be barriers to medication adherence that 
cannot be addressed using EMDs, especially in a high-risk, high-disease burden community. Our 
study participants were mostly made up of ethnic minorities of low-socioeconomic status with 
high asthma severity. The burden of disease in this study group was high, as indicated by the 
high rates of ED visits, hospitalizations, and oral steroid usage. In such a population, a 
multidisciplinary approach including care coordination efforts, is vital in addressing 
psychosocial and environmental factors (Burke et al, 2016). Factors such as parental stresses as 
well as childhood stress related to residence in low-income, inner-city communities negatively 
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influences asthma self-management, and is associated with morbidity and non-adherence (Butz 
et al, 2014). Additionally, as evidenced by our low return rate for follow-up visits, there may be 
additional issues related to access to care that could not have been addressed in this study. These 
factors are vital aspects of preventive care, especially in inner-city children with asthma (Butz et 
al, 2014). While EMDs may be able to address intentional non-adherence, and feedback may be 
able to tackle some aspects of non-intentional non-adherence, without consistent care 
coordination efforts, we cannot effectively address environmental factors that greatly influence 
asthma severity and disease burden. Additionally, there are practical considerations when 
addressing socioeconomic factors in the clinical setting. With increasing time restraints put on 
clinicians, it is increasingly difficult to effectively address both medical as well as social issues 
that patients may face. While the pulmonary clinic at Connecticut Children’s Medical Center is a 
specialty clinic, there are no consistent care coordination efforts in the form of care coordinators 
given to every child with asthma, limiting the resources that patients have access to. This, along 
with time limitations, could have greatly influenced the quality of feedback that participants 
received.  
Overall, despite lack of change in adherence seen in the intervention group, we saw that 
patient acceptability of the intervention was high after six months of use. Participants reported 
willingness to continue use as well as recommending use to others. Additionally, participants 
reported perceived control of asthma symptoms, and responded favorably to physician feedback. 
Of course, similar to other studies, our acceptability questionnaire was not validated (Chan et al, 
2016; Foster et al, 2012). We did not control for whether participants or parents answered the 
questionnaire. If the parent answered, it is uncertain the response was from the person who 
managed the participant’s asthma care. For participants, young children could have had difficulty 
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comprehending the language used in the questionnaires, and older children could have refused to 
complete questionnaires or provided inaccurate answers. Thus, further validation testing of the 
questions in this questionnaire would be needed.   
Several other limitations existed for this study. First, we did not have a study arm that 
only had EMDs with no phone app or feedback intervention. This made it difficult to compare 
EMD data between control and intervention groups. Additionally, we did not have a period of 
time with the EMD to accurately measure baseline adherence. Thus, our only way of measuring 
adherence that was consistent between groups was based on pharmacy refill data, which has been 
shown to be less accurate than EMDs (Jentzsch et al, 2009). Additionally, we did not control for 
who the app was given to, only that the app was given to whomever managed the child’s asthma 
at home. Thus, the intervention was not given to consistently address self-management of 
asthma, which means other parental factors could have influenced usage of the EMD and app. 
Another limitation to the study was the fact that we could not analyze any of the rescue data from 
the rescue EMD given to participants. We found that very few participants recorded any rescue 
inhaler use, which was the reason this data was not included for analysis. This was unlikely due 
to lack of rescue inhaler use, as evidenced by the poorly controlled asthma in our participants. 
This could be due to the fact many patients have multiple rescue inhalers – one for home, one for 
school - meaning we could not fully capture the full extent of use with only one tracker given to 
participants. Lastly, as this analysis was preliminary, the study cohort analyzed represents only a 
portion of all the participants in the trial. Further follow-up and recruitment would likely account 
for the seasonality of disease mentioned previously, as well as a better understanding of how this 
intervention could affect pediatric asthma. 
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CONCLUSION: 
In conclusion, this is the first study to our knowledge that looks at the feasibility as well 
as acceptability of using EMDs along with clinician feedback in a high-risk, high disease-burden 
community like Hartford, Connecticut. Our preliminary data did not show any significant 
changes to adherence after implementation of this intervention in children with persistent 
asthma. However, patient acceptability of EMDs was high despite technical issues related to the 
device which still needs to be resolved prior to use in the clinical setting. Overall, this study 
reinforces the fact that non-adherence to asthma controller medications in children remains 
suboptimal, especially in low-socioeconomic communities. Significant barriers to adherence still 
exist that may not be adequately addressed with EMDs alone, but EMDs could potentially offer 
greater insight into children’s health behaviors. Thus, further research as well as follow-up on the 
rest of the cohort of participants in this study is needed in order to elucidate the role that EMDs 
can play in the management of asthma in children and adolescents.  
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